Insights into selectivity of STI571 [GleevecTM] from X-ray crystallography

• Autorzy: Nowakowski J , Sridhar V. , Thompson D.A. , Cronin C.N. , Vaughn D.E. , Gangloff A.R. , Sang B.C. , Zoa H. , Knuth M.W. , Swanson R.V. , Snell G. , Mol C.D. , Wilson K.P. , Mcree D.E.
• Języki publikacji: EN

Słowa kluczowe

EN

small molecule; treatment; X-ray crystallography; drug; therapy; administration; food; kinase inhibitor; chronic myelogenous leukemia; tyrosine kinase

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2003
• Tom: 08
• Numer: 2A
• Opis fizyczny: p.556-557

Twórcy

autor

Nowakowski J

• Syrrx, Inc. 10410 Science Center Dr., San Diego, CA 92121, USA

autor

Sridhar V.

autor

Thompson D.A.

autor

Cronin C.N.

autor

Vaughn D.E.

autor

Gangloff A.R.

autor

Sang B.C.

autor

Zoa H.

autor

Knuth M.W.

autor

Swanson R.V.

autor

Snell G.

autor

Mol C.D.

autor

Wilson K.P.

autor

Mcree D.E.

Bibliografia

• 1. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schifer, C., Gambacorti-Passerini, C., Niederweiser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M. and Druker, B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346 (2002) 645-652.
• 2. Schaller, M.B. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim. Biophys. Acta 1540 (2001)1-21.
• 3. Nowakowski, J., Cronin, C.N., McRee, D.E., Knuth, M.W., Nelson, C.G., Pavletich, N.P., Rogers, J., Sang, B., Scheibe, D.N., Swanson, R.V. and Thompson, D.A. Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure 10 (2002) 1659-1667.
• 4. Schindler, T., Bornmann, W., Pellicena, P., Miller, T.W., Clarkson, B. and Kuryian, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942.
• 5. Nagar, B., Bornmann, W.G., Pellicena, P., Schindler, T., Veach, D.R., Miller, W.T., Clarkson, B. and Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD 173955 and imatinib (STI-571). Cancer Res. 62 (2002) 4236-4243.